Brotizolam
- Generic Name
- Brotizolam
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10BrClN4S
- CAS Number
- 57801-81-7
- Unique Ingredient Identifier
- 5XZM1R3DKF
- Background
Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).
Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.
- Indication
Brotizolam is indicated for 2-4 weeks in the treatment of severe or debilitating insomnia.
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.